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Abstract 
In the context of inflammation, osteopontin (Opn) is known to promote effector 
responses, facilitating a proinflammatory envi- ronment; however, its role during antigenic 
tolerance induction is unknown. Using a mouse model of asthma, we investigated the role 
of Opn during antigenic tolerance induction and its effects on associated regulatory 
cellular populations prior to disease initiation.  Our  experiments  demonstrate  that  Opn 
drives  protective  antigenic  tolerance  by  inducing  accumulation  of  IFN-b– producing 
plasmacytoid dendritic cells, as well as regulatory T cells, in mediastinal lymph nodes. We 
also show that, in the absence of TLR triggers, recombinant Opn, and particularly its 
SLAYGLR motif, directly induces IFN-b expression in Ag-primed plasmacytoid 
dendritic cells, which renders them extra protective against induction of allergic airway 
disease upon transfer into recipient mice. Lastly, we show that blockade of type I IFNR 
prevents antigenic tolerance induction against experimental allergic asthma. Overall, we 
unveil a new role for Opn in setting up a tolerogenic milieu boosting antigenic tolerance 
induction, thus leading to prevention of allergic airway inflammation. Our results 
provide insight for the future design of immunotherapies against allergic asthma.  
This is the author's accepted manuscript of the article published in Journal of Immunology. The 
final authenticated version is available online at: https://doi.org/10.4049/jimmunol.1701345 
Introduction 
 
Mechanisms of central and peripheral tolerance are crucial for maintaining immune system homeostasis 
and preventing exaggerated immune responses to intrinsically harmless self- or foreign Ags. Failure of 
this mechanism could lead to the development of chronic inflammation, such as allergic asthma and 
autoimmune diseases. Because the incidence of allergic disease has risen dramatically, much effort has 
been put into determining the control mechanisms of peripheral tolerance to allergens in an attempt to 
find a treatment or prevention strategy for allergic disease. Allergic asthma is a disease caused by 
aberrant TH2 immune responses to inhaled allergens leading to eosinophilic airway inflammation, 
mucus hypersecretion, and variable airway obstruction (1). Regulatory T (Treg) cells are important 
suppressors of dysregulated TH2 responses to inhaled Ags, because constitutive or induced deficiency 
of these cells leads to severe asthmatic reactions (2, 3). Likewise, several groups have demonstrated 
that conventional dendritic cells (cDCs) and plasmacytoid dendritic cells (pDCs) are key regulators of 
TH2 responses in allergic airway inflammation (4–7). As in many processes of immunoregulation, 
cytokines like TGF-b1 and IL-10 are also important regulators of tolerance to inhaled Ags (3, 8, 9). 
Osteopontin (Opn) is a cytokine expressed by immune cells, such as activated T cells and dendritic cells 
(DCs), as well as by non- immune cells, including tumor cells and stromal cells (10–12). In 
inflammatory conditions, Opn affects DC function (5, 13–18) and can drive TH1, TH2, and TH17 
effector immune responses (5, 11, 13, 14, 19, 20). In contrast, Opn is constitutively expressed by a great 
variety of cells under noninflammatory conditions (12, 21– 23), but its physiological significance is 
largely unknown. For example, secreted Opn (sOpn) is expressed in the bone marrow (BM) and also 
upon inflammatory conditions, primarily in the form of thrombin-cleaved fragments (24, 25). Opn 
fragments have binding motifs for several integrins: the SLAYGLR motif spe- cifically interacts with 
integrins a4b1, a9b1, and a4b7, whereas the RGD motif interacts with the avb3, avb5, avb1, and a5b1 
integrins (12, 26). In addition, the C-terminal half of Opn interacts with certain CD44 variants (12, 27). 
Thrombin cleavage of Opn reveals the otherwise cryptic SLAYGLR domain, and this modi- fication is 
vital for its interaction with a9b1 integrin (28). 
Recent reports show that Opn is expressed in Foxp3+ Treg cells (29, 30), suggesting its possible role in 
immune regulation. In this study, we test whether Opn affects tolerance induction during in- tranasal 
(i.n.) administration of endotoxin-free Ag. Our results un- veil a novel role for Opn as a tolerance 
enhancer against allergic airway disease, setting up an immunoregulatory milieu and poten- tiating 
CCR7-expressing pDC recruitment to the draining lymph nodes (dLNs). In addition, we reveal that, in 
the absence of pathogen-associated molecular patterns, sOpn, and specifically its integrin-binding 
SLAYGLR motif, induces low levels of IFN-b expression in Ag-primed pDCs. SLAYGLR-treated 
pDCs are highly efficient at suppressing allergic airway inflammation via type I IFN. Finally, we 
show that type I IFNs are crucial during antigenic tol- erance induction against allergic airway 
disease. 
 
Materials and Methods 
Mice 
BALB/c, C57BL/6J (B6), OVA-specific TCR-transgenic (Tg) C.Cg-Tg (DO11.10)10Dlo/J (DO11.10), 
C.129P2(B6)-IL-10tm1Cgn/J, B6(Cg)-Il10tm1.1Karp (Il10GFP), B6.129-Ifnb1tm1Lky/J   
(IfnbEYFP),   B6.129S2-Ifnar1tm1Agt/Mmjax (Ifnar12/2), and B6-Tg (C-type lectin   domain family 4, 
member C [CLEC4C]–heparin binding EGF like growth factor [HBEGF]) 956Cln/J (pDC-specific 
type II C-type lectin [BDCA2]-diphtheria toxin receptor–[DTR]) mice were purchased from The 
Jackson Laboratory (Bar Harbor, ME). B6-Tg Foxp3-DTR/EGFP (depletion of Treg cell [DEREG]) 
mice were provided by T.S. B6.129S6(Cg)-secreted   phosphoprotein   1   (Spp1)tm1Blh/J    (Spp12/2) 
mice were kindly provided by Dr. L. Liaw (Maine Medical Center Research Institute, Scarborough 
ME). All mice used in this study were 8–10-wk-old females. Mice were housed at the Animal Facility 
of the Biomedical Research Foundation of the Academy of Athens and at the University Hospital Ghent 
(Ghent, Belgium). Use of mice in this study was reviewed and approved by the Bioethics Committee 
of the Bio- medical Research Foundation of the Academy of Athens, the Veteri- narian Office of Attica, 
and the Animal Ethics Committee of Ghent University. All procedures were in accordance with the 
National In- stitutes of Health Statement of Compliance (Assurance) with Standards for Humane 
Care and Use of Laboratory Animals (A5736–01) and with the European Union Directive 86/609/EEC 
for the protection of ani- mals used for experimental purposes. 
 
In vivo experimental protocols 
For tolerance induction, mice received 200 mg of EndoGrade OVA (Hyglos) i.n. in the presence of 
2.5 mg recombinant Opn protein (rOpn) (R&D Systems), 72 ng of synthetic secreted Opn134–153 
fragments (frOpn; IVPTVDVPNGRGDSLAYGLR), or PBS (control). The RGD domain (Arg-Gly-
Asp) of frOpn1 is scrambled to RAA (Arg-Ala-Ala). The SLAYGLR domain (Ser-Leu-Ala-Tyr-Gly-
Leu-Arg) of frOpn2 is scrambled to LRAGLRS (Leu-Arg-Ala-Gly-Leu-Arg-Ser). frOpn3 has the 
RGD and SLAYGLR domains scrambled to RAA and LRAGLRS, respectively (Caslo Laboratory 
ApS). Opn oligopeptide fragments have been described previously (31). Myelin oligodendrocyte 
glycoprotein (MOG)35–55 peptide (MEVGWYRSPFSRVVHLYRNGK; Caslo Laboratory ApS) 
was also used for tolerance induction (250 mg per mouse 
i.n.). Mice were euthanized 36–40 h later and analyzed. In certain ex- periments, tolerance was induced 
prior to allergic airway disease in- duction: mice received 200 mg of EndoGrade OVA (i.n.) on days 
22, 21, and 0 in the presence of 2.5 mg of rOpn or 72 ng of frOpn1-3 synthetic fragments (i.n.). Control 
mice received PBS. Allergic airway disease (asthma) was subsequently induced: on day 10, mice were 
immunized with chicken OVA Grade V (Sigma-Aldrich; 50 mg) in 0.2 ml of aluminum hy- droxide 
(alum) (Serva), followed by three challenges with 5% aerosolized OVA between days 16 and 18, as 
described (5, 15). Mice were euthanized 2 d after the last aerosol treatment (on day 20). DEREG mice 
received 1 mg of diphtheria toxin (DT; Sigma-Aldrich) (32) or PBS i.p. on days 23 and 22 (6 h prior to 
i.n. OVA administration). For the DT control group, non-Tg littermates were administered DT. For pDC 
depletion, mice received 225 mg of 120G8 pDC-depleting Ab (IgG2a; Dendritics, Lyon, France) (33) 
or an IgG2a isotype control Ab i.p. on days 26, 25, 24, and 23. As in Fig. 4A, mice received 200 mg of 
EndoGrade OVA i.n., along with 2.5 mg of rOpn, on days 22, 21 and 0 and were euthanized 7 d later. For 
pDC depletion in BDCA2-DTR mice, 120 ng of DT was administered i.p. on days 24 and 23 in the 7-d 
tolerance-induction protocol (as in Fig. 4A) (34). Efficient pDC depletion ($95%) from dLNs in both 
approaches was determined by FACS analysis (data not shown). For neutralization of IFNAR1, mice 
received 
20 mg of a polyclonal affinity-purified neutralizing Ab to mouse 
IFNAR1 (clone MAR1-5A3; eBioscience) or goat IgG isotype control (R&D Systems) i.p. 2 h before 
tolerance induction. For allergy in- duction, after IFNAR1 neutralization and tolerance, mice were im- 




Lung function was measured in mice 24 h after the final OVA challenge (day 19) by whole body 
plethysmography (Buxco Technologies) to calculate enhanced pause (Penh). Responses to inhaled 
methacholine (Sigma-Aldrich) at concentrations of 3–100 mg/ml were measured for 1 min, as 
previously described (5). 
Analysis of bronchoalveolar lavage and lung histology 
Bronchoalveolar lavage (BAL) harvesting and analysis were performed as previously described (35, 
32). For histological analysis, paraffin-embedded (4-mm) lung sections were stained with H&E and 
quantified as previously described (35). Goblet cells were quantified in Periodic acid–Schiff (PAS)- 
stained lung sections (5). A semiquantitative scoring system was used to grade the area of lung 
infiltrated, as previously described (36). Goblet cells were counted on PAS-stained sections using an 
arbitrary scoring system, as previously described (36). 
pDC generation from BM, cultures, and adoptive transfer 
For pDC generation, BM cells were isolated and cultured with recombinant human Flt3 ligand, as 
described (37). On day 11, 7AAD2 CD32CD192CD11c+B220+PDCA1+Siglec-H+    pDCs    were    
sorted    to 98% purity using a FACSAria III, after enrichment with a CD11c MicroBeads Kit (Miltenyi 
Biotec). Sorted pDCs from BM cultures were conditioned for 16 h with 100 mg/ml EndoGrade OVA 
or LoTox Der- matophagoides pteronyssinus allergen 1 (Derp1; Indoor Biotechnol- ogies) in the 
presence of 250 ng/ml rOpn, 18.2 ng/ml frOpn1 or frOpn3, or PBS. After the culture with OVA, pDCs 
were washed and analyzed or transferred i.v. via the tail vein (106 cells per mouse). Allergic asthma 
was induced in mice 7 d later. Mice were euthanized 2 d after the last OVA challenge (Figs. 7B, 10A). 
Cell culture, proliferation, and cytokine analysis 
Isolated dLN cells (2 3 105–106) were cultured with 125 mg/ml OVA (Sigma-Aldrich) for 48 h. We 
performed proliferation assays with thymi- dine incorporation, as previously described (38). For certain 
experiments, proliferation of cells was measured as the percentage of Edu+ cells by FACS, using a 
Molecular Probes kit. For cytokine measurements, we used ELISA kits for IL-5 and IFN-g (both from 
BD Biosciences), IL-4 and IL-13 (both from R&D Systems), and IFN-b (BioLegend). 
 
Flow cytometry 
Freshly isolated live (7AAD2; BD Biosciences) dLN cells and in vitro– derived BM cells were stained 
with combinations of fluorochrome- conjugated Abs to CD4–Pacific Blue or CD4-PE/Cy5 (clone GK 
1.5); CD3-PE/Cy7, CD3-PE/Cy5, CD3-PE, or CD3-FITC (17A2); CD11c-PE/ Cy7, CD11c-FITC, or 
CD11c-Orange 605 (N418); CD11b-PE/Cy7 or CD11b-FITC (M1/70); B220-PE or B220-BV 510 
(RA3-6B2); CCR7-PE 
(4B12); Siglec-H–Pacific Blue or Siglec-H–FITC (551); PDCA-1–PE or PDCA-1–FITC (927); CD19-
PE/Cy7 or CD19-PE/Cy5 (6D5); CD25-PE (PC61.5) (BioLegend); and T1ST2 (DIH9) (T1ST2-FITC 
[MD Biosciences] or T1ST2–PE [BioLegend]). For intranuclear staining of Foxp3, a permeabilization 
kit and Abs (Foxp3–Pacific Blue or Foxp3-PE/CyC5; clone FJK-16s) were used (eBioscience). Flow 
cytometric measurements were performed using an Attune Acoustic Focusing Cytometer (Applied 
Biosystems) and a FACSAria III (BD). FACS sorting of pDCs was per- formed using a FACSAria III. 
Data analysis was performed with FlowJo software (TreeStar). 
Chemotaxis assay 
Sorted pDCs from lymph nodes (LNs) and spleen of BALB/c mice were treated with rOpn (500 ng/ml) for 
18–20 h and assayed for migration in response to chemokine CCL19 or CCL21 (200 ng/ml) (R&D 
Systems). The lower chambers of Transwell plates (QCM Chemotaxis Cell Migration Assay, 24- well 
[5 mm], colorimetric; Millipore) were filled with 500 ml of serum-free medium in the presence or absence 
of chemokines. DCs (105 cells per 200 ml) resuspended in serum-free medium were deposited in the upper 
chambers of the Transwell plates and allowed to migrate for 4 h at 37˚C in 5% CO2. For each experiment, 
pooled total cells from spleen and inguinal and mesenteric LNs of mice (n = 8) were used, and pDCs 
were isolated by sorting. 
 
Suppression assay and Treg cell induction in vitro 
BM-derived pDCs, pretreated or not with OVA and/or rOpn, were cultured with naive DO11.10 CD4+ 
T cells for 3 d at a 1:5 ratio. T cells were harvested and cultured in the presence of 1 ng/ml 
recombinant mouse IL-2 (R&D Systems) for an additional 7 d. Suppressive activity was assayed on 
105 freshly purified CFSE (Invitrogen)-labeled DO11.10 CD4+ T cells stimulated with 104 irradiated 
BALB/c splenocytes, with 1 mg/ml OVA 323–339 peptide (Caslo Laboratory ApS), in the presence 
or absence of 105 DC-stimulated T cells. CFSE uptake was assayed 7 d later (Fig. 7A). 
 
Quantitative real-time PCR analysis 
Total RNA was extracted from cells isolated from dLNs with anti– mPDCA-1 and CD11c MicroBeads 
(Miltenyi Biotec) and further purified with FACS sorting. cDNA synthesis was performed as 
described (31). Primers were designed using the Primer3 program and are shown in Supplemental 
Table I (MWG Eurofins). Hprt, Foxp3, Il-10, Il27p28, and Spp1 primers were described previously 
(31). Real-time PCR was performed and analyzed as previously described (31). The reference gene used 
for real- time PCR analysis was Hprt. 
Statistical analysis 
Data were analyzed using Prism 7 software (GraphPad). The two-tailed Student t test was used for 
statistical analyses of two-group comparisons. Multigroup comparisons were performed using two-
way ANOVA, followed by the Bonferroni correction for the multiplicity of tests. All results are 
presented as mean 6 SEM. In all experiments, statistical significance was defined as *p # 0.0332, **p 
# 0.0021, ***p # 0.0002, and ****p , 0.0001. 
 
Results 
Opn boosts antigenic tolerance leading to increased protection from allergic airway disease 
To address whether Opn plays a role in tolerance induction, mice received endotoxin-free chicken 
OVA, together with endotoxin-free rOpn or PBS control i.n., and protection against disease was 
assessed using a well-established model of allergic asthma (39) (Fig. 1A). OVA-tolerized mice showed 
a significant decrease in BAL total cells and eosinophils, as well as lung tissue inflammatory scores and 
mucus secretion (Fig. 1B, 1C), compared with nontolerized mice. In addition, Penh in OVA-tolerized 
mice was significantly reduced (Fig. 1D). Importantly, in OVA/rOpn- tolerized mice, numbers of 
eosinophils in BAL (Fig. 1B), airway hyperresponsiveness (AHR) (Fig. 1D), lung leukocytic 
infiltration, and mucus secretion (Fig. 1C) were further reduced compared with OVA-tolerized mice. 
Further- more, OVA/rOpn tolerization resulted in significantly reduced levels of IL-4, IL-13, and IFN-g 
in BAL, as well as a reduction in OVA- specific responses in mediastinal lymph node (mLN) cell 
cultures and in TH cell proliferation, compared with OVA tolerization (Fig. 1E–G). Studies from our 
group (5, 15) and other investigators (40–42) have shown that there are high levels of IFN-g production 
in allergic airway disease. The above findings indicated that administration of Opn, along with OVA, 
promotes enhanced toler- ance, conferring significant protection from disease development. 
We next investigated whether Opn deficiency had any effect on tolerance induction. Tolerance 
induction in Spp12/2 mice was not as effective as in Spp1 mice, because we did not note a significant 
change in the number of eosinophils or total cell numbers in BAL (Fig. 2A). In accordance, tolerogenic 
i.n. OVA administration in Spp12/2 mice could not efficiently dampen the inflammation and mucus 
secretion in the lung, whereas it was very efficient in Spp1+/+ mice (Fig. 2B). TH2 cytokine production by 
OVA–stimulated mLN cells was also lower in OVA-tolerized Spp12/2 mice compared with PBS-treated 
Spp12/2 mice (Fig. 2C). OVA-stimulated mLN cells 
from OVA-tolerized Spp1+/+ mice produced ∼50% lower levels of 
TH2 cytokines compared with cells from PBS-treated Spp1+/+ mice, 
whereas OVA-tolerized Spp12/2 mice had a smaller reduction in cytokine levels compared with 
Spp1+/+ mice (Fig. 2C). The reduction in IFN-g levels was similar among groups (Fig. 2C). Finally, 
OVA tolerization of Spp12/2 mice resulted in a smaller decrease in the percentages of CD3+ T 
proliferating cells in cultures of mLN cells compared with those from Spp1+/+ OVA-treated mice (Fig. 
2D). The above results strongly support that tolerance induc- tion is more effective in the presence of 
Opn. 
Opn administration along with Ag increases accumulation of tolerogenic pDCs 
Migratory nonlymphoid tissue DCs transporting Ags to LNs are involved in promoting tolerance to self-
antigens in the steady-state. Because pDCs constitute a tolerogenic DC subset (43–47), and Opn has a 
dual role in the recruitment of DC subsets (5), we ana- lyzed pDC numbers in dLNs of OVA-tolerized 
mice and PBS-treated controls (Fig. 3A). Numbers of dLN pDCs were increased in the OVA-treated 
group compared with the PBS control group (Fig. 3B). Mice treated with OVA/rOpn had increased 
percentages and sig- nificantly higher total numbers of pDCs in the dLNs at 36–40 h following 
treatment compared with OVA treatment (Fig. 3B). In contrast, cDC numbers in the dLNs of 
OVA/rOpn mice were significantly reduced and percentages were lower compared with OVA 
treatment alone (Fig. 3B). Therefore, administration of Opn during tolerance induction affects the 
balance of DC subsets in dLNs by increasing the numbers of pDCs and re- ducing the numbers of 
cDCs. 
The importance of Opn for DC subset recruitment in tolerance was also demonstrated using Opn-
deficient mice. Antigenic tol- erance induction in Spp12/2 mice resulted in a significant re- duction in 
pDC numbers in their dLNs compared with Spp1+/+ mice (Supplemental Fig. 1). At the same time, cDC 
numbers were significantly increased in dLNs of Spp12/2 mice (Supplemental Fig. 1). Conclusively, 
these results show that tolerogenic admin- istration of OVA in an Opn-efficient microenvironment 
enhances pDC accumulation in dLNs. 
 
Administration of Opn during tolerance induction regulates CCR7 expression affecting DC subset 
homing to dLNs 
To explore the reason for the increased numbers of pDCs in dLNs of Opn-treated mice, we investigated 
the effect of Opn on CCR7+ pDCs. CCR7 is a chemokine receptor responsible for homing of DCs to 
dLNs (48–50). We quantified CCR7+ DC subsets in pe- ripheral blood 36 h following OVA/rOpn 
tolerogenic administra- tion (Fig. 3A). The percentages of CCR7+ pDCs per total pDC numbers were 
significantly elevated in the peripheral blood of mice treated with rOpn during tolerance induction 
compared with PBS-treated mice (Fig. 3C). The percentages of CCR7+ cDCs per total cDC numbers 
originating from the peripheral blood of mice that had been administered OVA/rOpn were significantly 
de- creased compared with OVA-administered mice (Fig. 3C). Our results demonstrate that Opn leads 
to enhanced migratory CCR7+ pDC percentages per total pDCs in the blood. 
We also found that OVA/rOpn-administered mice had signifi- cantly higher levels of Ccl19 and 
Ccl21 (encoding CCL19 and CCL21 chemokines that bind to CCR7) expression in their dLNs 
compared with OVA-administered mice (Fig. 3D), possibly attracting the increased numbers of CCR7+ 
pDCs to dLNs. Indeed, in vitro transmigration assays showed that sorted pDCs from naive mice 
pretreated with rOpn had a 2-fold increase in CCL19-induced chemotaxis compared with PBS-treated 
pDCs (Fig. 3E). The above findings demonstrate that, during toler- ance induction, Opn can 
differentially regulate the percentages of CCR7+ DC subsets, thereby affecting their chemotactic 
migration to dLNs in favor of pDCs. Moreover, the observed increased gene expression of the CCR7 
ligands CCL19 and CCL21 provide an extra explanation for the rOpn-mediated migration of pDCs to 
dLNs. 
Opn enhances pDC-dependent Foxp3+ Treg cell accumulation and promotes an immunoregulatory 
milieu in dLNs 
Because Ag administration for tolerance induction leads to gen- eration of Treg cells (51), we 
investigated whether Opn had an effect early on this process. We administered OVA with rOpn 
(OVA/rOpn) or PBS i.n. to mice for three consecutive days, and mice were analyzed 1 wk later (Fig. 
4A). OVA/rOpn-treated mice showed a nearly 2-fold increase in the percentages, as well as in the total 
numbers, of CD4+Foxp3+ Treg cells in dLNs compared with OVA-treated mice (Fig. 4B). Increased 
numbers of Foxp3+ Treg cells in OVA/rOpn-tolerized mice were accompanied by significantly 
enhanced Foxp3 expression in dLN cells (Fig. 4C). In addition, OVA/rOpn treatment induced a 
significant increase in the expression levels of immunoregulatory molecules, such as Il10, Ido, Tgfb1, 
Fgl2, and Il27, in dLNs compared with OVA treatment (Fig. 4C). Conclusively, Opn administration, along 
with Ag, promotes Foxp3+ Treg cell accumulation, resulting in a highly tolerogenic microenvironment 
in the dLN. 
To directly test whether increased numbers of Foxp3+ Treg cells mediate the observed rOpn 
promotion of tolerance, we depleted Foxp3+ Treg cells prior to tolerance induction using DEREG mice 
(52) (Fig. 5A). Induction of tolerance with rOpn could not protect Treg-depleted mice, which 
exhibited increased allergic responses, as demonstrated by increased eosinophilia and lymphocytosis 
in the BAL, increased T cell proliferation, elevated lung inflammation with enhanced mucus 
production, and increased OVA-specific cytokine responses compared with Treg-sufficient mice (Fig. 
5B–E). 
To address whether the Opn-mediated increase in pDC numbers was responsible for the observed 
accumulation of Foxp3+ Treg cells, we depleted pDCs by administering 120G8 pDC-depleting Ab 
(33) prior to induction of tolerance and examined the accu- mulation of Foxp3+ Treg cells in dLNs. 
This depletion led to a significant reduction in CD4+Foxp3+ Treg cell numbers compared with 
OVA/rOpn administration in non–pDC-depleted mice (Fig. 6A), resulting in exacerbated allergic 
airway disease (Fig. 6B). We observed similar effects of rOpn on Treg cellularity in LNs after in vivo 
depletion of pDCs in BDCA2-DTR Tg mice 
(34) (Supplemental Fig. 2). Thus, Opn-mediated pDC accumula- tion is responsible, at least in part, 
for the higher numbers of Treg cells in dLNs. In addition, dLN cells from OVA/rOpn-treated 
pDC-depleted mice were significantly less capable of suppress- ing OVA-specific T cell proliferation 
(Fig. 6C) compared with dLN cells from OVA/rOpn-treated non–pDC-depleted mice, reaching an 
even lower suppressive ability than that of OVA- treated pDC-depleted dLN cells. Thus, 
OVA/rOpn treatment increased the numbers of pDCs, favoring the accumulation of Foxp3+ Treg 
cells that are crucial for tolerance maintenance. 
Opn treatment of pDCs increases their suppressive activity against allergic airway disease 
We tested the suppressive function of in vitro OVA/rOpn-treated BM-derived pDCs by coculturing 
them with CD4+ T cells. T cells obtained from OVA/rOpn-treated pDC cultures signifi- cantly 
suppressed the responses of DO11.10 T cells to OVA compared with T cells obtained from OVA-
treated pDC cultures (Fig. 7A). We also adoptively transferred BM-derived pDCs, which were 
preconditioned in vitro with OVA or OVA/rOpn, into recipient mice prior to induction of allergic airway 
inflammation (Fig. 7B). 
Control mice received PBS-treated pDCs. Total and eosinophil cell numbers, as well as lung tissue 
inflammatory scores and mucus secretion, were lower in BAL of OVA/rOpn-treated pDC recipient 
mice compared with OVA-treated pDC recipient mice (Fig. 7B, 7C). Furthermore, OVA/rOpn-treated 
pDC recipients had significantly reduced OVA-specific responses compared with OVA-treated pDC 
recipients (Fig. 7D). Thus, OVA/rOpn treatment of pDCs rendered them more regulatory, indicating 
that Opn af- fects the intrinsic tolerogenic function of pDCs. 
Opn SLAYGLR motif is responsible for pDC recruitment and effective protection from allergic 
disease 
RNA expression analysis revealed that, during tolerance in- duction, mLN pDCs have increased 
expression of integrins avb3, a4b1, and a9b1 (data not shown). Because the SLAYGLR motif of 
Opn interacts with a4b1, a4b7, and a9b1 integrins (12), and the RGD motif interacts with the avb3 
integrin (11, 12), we asked which Opn domain is responsible for the observed effects on pDCs 
during tolerance induction. Thus, synthetic frOpn134–153, containing the RGD and the SLAYGLR 
integrin binding motifs, either intact or scrambled (31), were used with OVA to induce tolerance in 
mice, allowing us to unveil the involvement of the different integrin-binding motifs of Opn in pDC 
recruitment (Fig. 8A). frOpn134–153 rep- resents the thrombin cleaved fragment of Opn that reveals the 
otherwise cryptic domain SLAYGLR (28). OVA/frOpn1, con- taining an intact SLAYGLR motif but 
a scrambled RGD motif, induced the accumulation of higher numbers of pDCs in LNs compared with 
OVA and OVA/rOpn (Fig. 8A). Conversely, frOpn2, which contains an intact RGD, but a scrambled 
SLAYGLR motif, induced a reduction in pDC numbers in dLNs compared with all other treatments 
(Fig. 8A). When both motifs were scrambled, as in the case of frOpn3, the numbers and percentages 
of pDCs were not significantly altered compared with OVA (Fig. 8A, Supplemental Fig. 3A). 
OVA/frOpn1 in- duced higher percentages of pDCs in dLNs compared with OVA and OVA/frOpn3 
(Supplemental Fig. 3A). These data revealed that the Opn SLAYGLR motif is responsible for pDC 
accumulation in dLNs. These data also reveal that the RGD motif suppresses this accumulation. 
To examine the in vivo tolerogenic potential of frOpn1 in al- lergic disease, mice were treated with 
OVA, together with frOpn1 or frOpn3 for control, before the induction of allergic airway inflammation 
(Fig. 8B). OVA/frOpn1 was more successful than OVA/frOpn3 in promoting tolerance and, thus, 
protecting mice against allergic airway inflammation, as demonstrated by lower Penh values (Fig. 8C). 
BAL eosinophilia, as well as inflamma- tory score and mucus staining, was also dampened after OVA/ 
frOpn1 treatment (Fig. 8D). In addition, treatment with OVA/ frOpn1 led to reduced levels of   
OVA-specific   responses (Fig. 8E) and numbers of T1ST2+CD4+ T cells in dLNs (Fig. 8D). 
Collectively, this dataset indicates that the Opn SLAYGLR motif significantly boosts tolerance. 
Opn SLAYGLR motif induces IFN-b expression in pDCs 
We further asked whether OVA/frOpn1 treatment affects in vivo pDC immune profile   36–40   h   
after   tolerance   induction (Fig. 3A). In vitro, OVA/frOpn1 conditioning of pDCs promoted a 2-fold 
increase in Ifnb mRNA expression at 16 h (Fig. 9A). The observed difference in Ifnb expression was 
also reflected in the amount of IFN-b secreted, which was 5-fold higher in OVA/ frOpn1-conditioned 
pDCs compared with OVA/frOpn3- conditioned pDCs (Fig. 9B). House dust mite endotoxin-free 
Derp1 was also used to test whether the increased IFN-b response could be observed using another 
allergen. Indeed, Derp1/frOpn1 in vitro–conditioning of pDCs resulted in higher Ifnb expression 
compared with Derp1/frOpn3 (Fig. 9C). We also measured higher levels of Ifnb expression in 
OVA/rOpn- conditioned pDCs compared with OVA/PBS-conditioned pDCs (Supplemental Fig. 3B). 
RNA expression analysis using mLN pDCs isolated from mice treated with OVA versus OVA/rOpn 
showed differential expression of Ifnb compared to mice treated with OVA (data not shown). We found 
that, indeed, Ifnb expression was upregulated in mLN pDCs isolated from mice treated with 
OVA/frOpn1 compared with those isolated from mice treated with OVA/frOpn3 (Fig. 9E). To confirm 
the changes in IFN-b expression in vivo, we used IFN-bEYFP reporter mice. OVA/frOpn1-tolerized 
mice had significantly increased numbers of IFN-bEYFP+ pDCs and higher IFN-b expression per pDC 
(mean fluorescence intensity [MFI]) compared with OVA/frOpn3-tolerized mice (Fig. 9D). To test 
whether this effect is relevant to the Ag used, we tolerized IFN-bEYFP mice with a self-antigen, 
MOG35–55, with frOpn1 or frOpn3. MOG35–55/frOpn1 administration to   IFN-bEYFP mice   resulted in 
significantly increased accumulation of IFN-bEYFP+ pDCs and IFN-b expression per pDC (MFI) in 
LNs (Fig. 9F). However, the increase was modest compared with Opn/OVA, possibly because MOG 
is a peptide. These results suggest that, under tolerogenic conditions, the Opn SLAYGLR motif 
can boost Ifnb expression in pDCs through a mechanism in- dependent of the Ag used. 
Opn/SLAYGLR-induced IFN-b in pDCs is protective against allergic disease 
pDCs were primed in vitro with endotoxin-free OVA and frOpn1 or frOpn3 and transferred into mice prior 
to induction of allergic airway inflammation (Fig. 10A). Recipient mice were Ifnar1+/+ or Ifnar12/2. 
pDCs treated with frOpn1 were significantly more potent at protecting Ifnar1+/+ mice against allergic 
airway in- flammation, as demonstrated by reduced lung airway inflamma- tion, BAL eosinophilia, and 
goblet cell hyperplasia, compared with the control and OVA groups (Fig. 10A). Similar enhanced 
protection was also observed when pDCs were treated with rOpn and adoptively transferred into 
Ifnar1+/+ mice (Fig. 7B–D). Ac- tually, type I IFN produced by pDCs was crucial in maintaining this 
protective effect, because Ifnar12/2 recipient mice were not protected against allergic asthma (Fig. 10A). 
These results dem- onstrate that the integrin-binding SLAYGLR domain of Opn renders pDCs more 
regulatory through type I IFN production in the context of allergic airway inflammation. In fact, pDCs 
cannot preserve their regulatory function in recipients that lack expres- sion of type I IFNR. Finally, 
neutralization of IFNAR1 during the OVA tolerance-induction phase (Fig. 10B) resulted in reduced 
protection from allergic airway disease concomitant with in- creased eosinophilia in BAL (Fig. 10C) 
and increased OVA- specific responses (Fig. 10D). This indicates that type I IFN is absolutely 

























In this article, we unveil a new role for Opn, and particularly its SLAYGLR motif, in setting up a 
tolerogenic milieu driving anti- genic tolerance induction and, thus, leading to protection from allergic 
airway inflammation. The respiratory mucosa is constantly being exposed to a myriad of 
nonpathogenic environmental Ags. To protect against the im- munopathological consequences of this 
constant stimulus, a default low noninflammatory TH2 mechanism and/or a T cell–mediated tolerance 
mechanism is activated (53). The mechanism underlying these processes is not fully understood. In 
this study, we initially demonstrate that Opn induces tolerance by tilting the pDC/cDC balance in favor 
of anti-inflammatory pDCs, via differentially regulating their CCR7 expression. CCR7-dependent 
homing of DCs into dLNs is required for the induction of tolerance (50). 
Opn promotes TH2 effector responses when administered during the allergen-sensitization phase (5). 
In contrast, we have previ- ously shown that Opn inhibits TH2 responses during allergen challenge, 
and administration of rOpn during that phase is sup- pressive for experimental allergic asthma (5). In 
this study, we explore the role of Opn during a different phase, which is when Ag is administered 
during tolerance induction, prior to sensitiza- tion. Thus, Opn is administered i.n., prior to the 
sensitization phase, along with the allergen (antigen), to test its effects upon antigenic tolerance 
induction. Together, our results from this study, as well as from a previous study (5), show that 
adminis- tration of Opn during antigenic tolerance induction and during antigenic challenge is 
protective and, thus, can be used as a pre- ventive or a therapeutic agent against allergic airway 
disease. 
Regulatory cytokines, such as Tgfb1, Il10, and Fgl2, and mol- ecules, such as Ido (54), were 
substantially upregulated in our Opn-driven tolerance model, creating an immunoregulatory 
microenvironment in the dLN. This tolerogenic milieu was accompanied by the accumulation of 
Foxp3+ Treg cells, which are very important for induction of tolerance (51). Mice that had en- hanced 
Treg cell numbers due to rOpn administration showed suppressed effector responses and were 
protected from allergic disease. When Foxp3+ Treg cells were depleted, Opn-mediated tolerance 
boosting was abolished. In light of its well-established proinflammatory function (10–12), it was 
unexpected that Opn could be an inducer of Treg cell accumulation in vivo. In the absence of pDCs, 
rOpn administration was no longer capable of inducing increased numbers of Foxp3+ Treg cells in 
dLNs, demonstrating that rOpn affects Treg cell numbers primarily through its impact on pDCs. In contrast, 
after tolerance induction without the addition of Opn, Treg cell numbers do not appear to depend on pDCs, 
because pDC depletion did not reduce their numbers. These results show that rOpn conditions pDCs to 
enhance Treg cell accumulation. Functional flexibility and fostering of Treg cell responses are typical 
features of pDC involve- ment in tolerance (4, 46), as also revealed by our studies. 
Thrombin cleavage of Opn occurs during homeostatic and inflam- matory conditions (24, 25), and 
conformational changes after thrombin cleavage result in higher-affinity binding to certain receptors (26). 
In fact, the cryptic SLAYGLR motif is revealed upon thrombin cleav- age of Opn, which is vital for its 
interaction with a9b1 integrin (28). Because the SLAYGLR motif of Opn protein interacts with a4b1, 
a4b7, and a9b1 integrins (12), and the RGD motif in- teracts with the avb3 integrin (11, 12), we used 
synthetic frOpn134–153, containing both integrin binding motifs (intact or scrambled) (31). Thrombin 
cleavage of Opn also produces a fragment containing the C-terminal half of Opn, which interacts with 
certain CD44 variants (12, 27). In our settings, as well as in other settings (31, 55, 56), frOpn134–153 
has a greater efficiency compared with full-length Opn. Thus, it is possible that inter- action of Opn 
with CD44 interferes with certain Opn effects, such as pDC recruitment. Future investigations will 
elucidate the role of Opn–CD44 interactions in tolerance induction. 
Under endotoxin-free conditions, we demonstrated that the SLAYGLR domain of Opn (frOpn1) 
enhances IFN-b expression in pDCs exposed to protein or peptide Ag. Accordingly, we showed that 
adoptively transferred OVA/frOpn1-treated pDCs were more efficient at suppressing allergic airway 
inflammation in recipient mice. This regulatory function was indeed mediated by the ob- served 
upregulated production of IFN-b by pDCs, because Ifnar12/2 recipient mice were not protected against 
allergic asthma. During the course of allergic airway inflammation, pDCs, as well as their type I IFN 
production, are suppressive for disease (4, 57–59). Our studies reveal that pDCs expressing higher IFN-
b levels due to exposure to Opn are important for protective toler- ance prior to disease induction. 
Importantly, our experiments point to a crucial role for type I IFNs during the induction of efficient 
antiallergic antigenic tolerance. Accordingly, IFNAR signaling promotes Treg cell development and 
function under stress conditions (60). 
Opn administered during tolerance also resulted in a remarkable upregulation of the ligands of CCR7, 
CCL19, and CCL21 in dLNs, reminiscent of that observed in tumors (61). Specifically, high CCL21 
expression by melanoma in mice was associated with an immunotolerant microenvironment, which 
included the induction of lymphoid-like reticular stromal networks, an altered cytokine mi- lieu, and, 
most importantly, the recruitment of regulatory leukocyte populations (61). High Opn expression is 
prevalent in many types of malignancy (62); although Opn is considered proinflammatory, most of these 
tumors escape immune surveillance. Thus, it is pos- sible that Opn and its mediated induction of CCL21 
could also be involved in suppression of antitumor immunity. 
In this article, we demonstrate that the SLAYGLR motif of sOpn enhances regulatory mechanisms when 
administered together with endotoxin-free Ag in a tolerogenic context. In this respect, Opn has a unique 
effect on immunity, differing substantially from its effects in the presence of danger signals. The 
SLAYGLR motif of Opn interacts with integrins (12). Addressing which integrin mediates the 
tolerogenic effects of the SLAYGLR motif of Opn on Ag- loaded pDCs, and primarily the induction 
of IFN-b, will assist in the design of therapies targeting tolerance in allergy. Finally, our results point 
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FIGURE 1. Opn administration boosts antigenic tolerance, leading to increased protection from allergic airway disease. (A) Experimental 
protocol used for endotoxin free-tolerance (OVA administration) induction, followed by allergic asthma induction. Controls were mice pretreated 
with PBS (no tolerance) and sub- sequent allergic airway disease induction (white bars). Controls for allergic airway disease were mice pretreated 
and sensitized with PBS. (B) Total cell counts (in BAL) and eosinophils. (C) Representative photomicrographs of H&E- and PAS-stained lung sections 
and histological scores. Scale bars, 100 mm. (D) AHR (depicted as Penh) on day 19. Levels of IL-4, IL-13, and IFN-g in BAL (E) and in the 
supernatant of mLN cells (F) stimulated ex vivo with OVA. (G) [3H]Thymidine incorporation of mLN cells stimulated ex vivo with OVA. The same 
numbers of pooled mLN cells were cultured in 3, 4, 10, or 12 different wells per group in (E)–(G). Data are mean 6 SEM (n = 8 mice per group), one 












FIGURE 2. Spp12/2 mice are more resistant to tolerance induction. Spp12/2 or Spp1+/+ mice received three doses of endotoxin-free OVA or 
PBS i.n. on days 22, 21, and 0 (as in Fig. 1A). On day 10, mice were sensitized i.p. with OVA in alum and were subsequently challenged 
through the airways with aerosolized OVA between days 16 and 18. Analysis was performed on day 20. (A) Differential eosinophil and 
total cell counts in BAL. (B) Lung inflammation in H&E- stained sections and mucus secretion in PAS-stained sections from PBS- and OVA-
treated Spp1+/+ and Spp12/2 mice. Scale bar, 100 mm. Levels of IL-4, IL-5, IL-13, and IFN-g in supernatants of OVA-stimulated dLN cells 
(C) and percentages of Edu+CD3+CD4+ T cells in OVA-stimulated dLN cells (D) in both mice groups. The same numbers of pooled mLN 
cells were cultured in three, six, or eight different wells per group in (C) and (D). Data are mean 6 SEM (n = 6 mice per group), one 









FIGURE 3. Opn-induced accumulation of pDCs in dLN and differential CCR7 expres- sion. Treatment of mice with endotoxin-free OVA 
(tolerance induction), together with endotoxin-free rOpn (A) or treatment of mice with PBS without OVA for control (B–D). Controls (without 
tolerance) were PBS- treated mice (white bars). (B–D) 7AAD2 CD32CD192CD11c+PDCA-1+CCR7+ pDCs and 
7AAD2CD32CD192CD11c+CD11b+ CCR7+ cDCs quantified in dLNs by flow cytometry. (B) Representative percentages in flow cytometric 
plots and numbers of dLN pDCs (upper panels) and cDCs (lower pan- els). (C) Representative flow cytometric plots and percentages of peripheral 
blood CCR7+ pDCs and cDCs among total pDCs and cDCs, respectively. (D) Relative expression to Hprt of Ccl19 and Ccl21 in dLNs of tolerized 
mice. Data are mean 6 SEM (n = 10 mice per group; cDNAs were pooled from three separate experiments). (E) Sorted pDCs from LNs and 
spleens of naive BALB/c mice were pulsed with vehicle or rOpn for 24 h and then subjected to transmigrate in response to CCL19. Numbers of 
migrating PBS-treated pDCs (white bars) or rOpn- treated pDCs (black bars). Triplicate wells of pooled pDCs sorted from spleens and LNs (n = 
8). Data are mean 6 SEM (n = 5–8 mice per group), one representative of five independent experi- ments (A–C) and from three independent 












FIGURE 4. Opn administration with Ag promotes accumulation of Treg cells and immunoregulatory gene expression in dLNs. (A) Mice 
received three doses of endotoxin-free OVA for tolerance induc- tion, along with rOpn or PBS. Controls (without tolerance) were PBS-
treated mice (white bars). (B) Percentages and numbers of CD3+CD4+Foxp3+ T cells quantified in dLNs by flow cytometry at day 7. (C) 
Relative expression to Hprt of immuno- regulatory genes in dLNs. cDNAs were pooled from three separate experiments. Data are mean 6 




























FIGURE 5. Opn-induced tolerance is Treg cell dependent. (A) Tolerance induction in DT-treated DEREG and control DEREG mice 
without DT injections. Controls (without tolerance) were DEREG mice pretreated with PBS, with subsequent allergy induction (white 
bars). (B) Eosinophil and total cell counts in BAL. (C) Numbers of Edu+CD3+CD4+ T cells per 25 3 104 OVA-stimulated dLN cells. (D) 
Lung inflammation and mucus se- cretion in H&E-stained (upper panels) and PAS-stained (lower panels) slides. Scale bars, 100 mm. (E) 
Levels of IL-5 and IL-13 in supernatants of OVA-stimulated dLN cells. The same numbers of pooled mLN cells were cultured in three (C) 
or six (D) different wells per group. Data are mean 6 SEM (n = 6 mice per group), one representative of three independent experiments. 



















FIGURE 6. Opn-induced tolerance in- creases pDC numbers, favoring Treg cell accumulation. (A) Mice received four doses of 120G8 
pDC-depleting Ab or Ig control i.p. on days 26, 25, 24, and 23, followed by tolerance induction for Treg cell generation, with or without 
rOpn ad- ministration. (B and C) Also, allergic air- way disease was subsequently induced on day 10. Control mice were pretreated with 
PBS (A) or sensitized with PBS (B and C). (A) Representative percentages in flowcytometric plots (left panel) and numbers of Treg cells 
(CD3+CD4+Foxp3+) accu- mulated in dLNs (right panel). (B) Eosin- ophil counts in BAL of allergic mice. (C) [3H]Thymidine 
incorporation in OVA- stimulated dLN cells. Quadruplicate wells of pooled mLN cells. Data are mean 6 SEM (n = 5 mice per group), one 













FIGURE 7. rOpn treatment of pDCs increases their suppressive activity against allergic airway disease. (A) [3H]Thymidine incorporation 
in co-cultures of DO11.10 T cells preconditioned with OVA323–339 and rOpn- treated pDCs with responder DO11.10 T cells. The same 
numbers of cells were cultured in five different wells per group. Data are mean 6 SEM, one representative of three independent experiments. 
(B) Sorted pDCs pre- conditioned in vitro with PBS or OVA or OVA/rOpn were adoptively transferred to recipient mice before the induction 
of allergic airway in- flammation. Total and eosinophil cell count in BAL were evaluated (day 20). Histological assessment of lung 
inflammation (H&E scoring) and lung mucus production (PAS score) (C) and levels of IL-4 and IL-13 (D) in supernatants of OVA-
stimulated mLN cells. Different wells of pooled mLN cells. Data are mean 6 SEM (n = 6–8 mice per group), one repre- sentative of three 
















FIGURE 8.    Opn SLAYGLR motifs boost tolerance by enhancing pDC recruitment to protect from al- lergy. (A) Numbers of dLN 
7AAD2 CD11c+B220+PDCA1+Siglec-H+ pDCs osinophil cell count in BAL, his- tological assessment of lung inflam- mation (H&E scoring) and lung 
mucus production (PAS score), and numbers of T1ST2+CD4+ TH2 cells in mLNs. after 40 h of tolerance induction with EndoGrade OVA i.n., along 
with rOpn, frOpn1, frOpn2, frOpn3, or PBS (as in Fig. 3A). (B) Mice were                                                                                                                             
treated with OVA/frOpn during tolerance induction before allergic air- way disease induction in (C)–(E). Control mice were pretreated with PBS, and 
allergy was subsequently induced (white bars). (C) AHR (depicted as Penh) at day 19. (D) Eosinophil cell count in BAL, histological assessment of 
lung inflammation (H&E scoring) and lung mucus production (PAS score), and numbers of T1ST2+CD4+ TH2 cells in mLNs. (E) Levels of IL-4, 
IL-5, and IL-13 in supernatants of OVA- stimulated mLN cells. The same numbers of pooled mLN cells were cultured in four to six different wells 
per group. Data are mean 6 SEM (n = 5, mice per group), one representative of three independent experiments. *p # 0.0332, **p # 0.0021, ***p # 




FIGURE 9. Opn SLAYGLR motif induces IFN-b production from pDCs. (A) Relative Ifnb expression to Hprt in pDCs conditioned in 
vitro with OVA/ frOpn1 or OVA/frOpn3. (B) Levels of IFN-b in the supernatants of the same cultures. (C) Relative Ifnb expression to Hprt 
in pDCs conditioned in vitro with Derp1/frOpn1 compared with Derp1/frOpn3. (D) Representative percentages in flow cytometric plots 
and numbers of 7AAD2CD32CD192CD11c+PDCA- 1+Siglec-H+IFN-bEYFP+ pDCs in dLNs of PBS-treated or OVA-tolerized mice and 
geometrical MFI (gMFI) of IFN-b-expressing pDCs. (E) Relative Ifnb 
expression to Hprt in pDCs isolated from dLNs of OVA/frOpn3- and OVA/frOpn1-tolerized mice. (F) Representative percentages in flow 
cytometric plots and numbers of total 7AAD2CD32CD192CD11c+PDCA-1+Siglec-H+IFN-bEYFP+ pDCs and gMFI of IFN-b–
expressing pDCs in dLNs of mice treated with PBS or tolerized with MOG35–55/frOpn3 or MOG35–55/frOpn1. Mice were tolerized as 
in Fig. 3A. Data are mean 6 SEM (n = 6–8 mice per group), pooled data from three independent experiments. *p # 0.0332, **p # 































FIGURE 10. Opn/SLAYGLR-induced IFN-b in pDCs renders them protective against allergic disease. (A) Isolated Ifnar1+/+ pDCs were 
primed in vitro with OVA and frOpn1 or frOpn3 or with PBS and adoptively transferred to Ifnar1+/+ or Ifnar2/2 mice. Histological scores for 
airway inflammation and goblet cell hyperplasia in lung sections stained with H&E and PAS, respectively, and number of eosinophils present 
in BAL. (B) OVA tolerance induction with the use of blocking Ab against IFNAR1 or isotype control prior to allergic airway disease 
induction. Control mice were pretreated with PBS prior to allergic airway disease induction (white bars). (C) Numbers of eosinophils in 
BAL and (D) levels of IL-4 and IL-13 in supernatants of OVA-stimulated dLN cells. The same numbers of pooled mLN cells were cultured 
in three or seven different wells per group. Data are mean 6 SEM [n = 4 or 5 mice per group (A) and n = 6 mice per group (B–D)], one 





















Supplemental Figure 1. Opn increases the numbers of pDCs. Mice were
pretreated with endotoxin-free OVA or PBS and analyzed after 40 hrs as in Figure
3a. Numbers of 7AAD–CD3–CD19–CD11c+CD11b–B220+PDCA-1+ pDCs in dLNs
and 7AAD–CD11c+CD11b+PDCA-1– cDCs from dLNs of Spp1+/+ or Spp1–/– mice.
Values are expressed as mean ± SEM (n=4 mice per group), one representative




















Supplemental Figure 2. pDC deletion in BDCA2-DTR mice abrogates
Treg cell accumulation in Opn-induced tolerance. For pDC depletion mice
received diphtheria toxin (DT) on days -4, -3 followed by tolerance induction
for Treg cell generation. Control mice were treated with PBS. Numbers of
Treg cell (CD3+CD4+Foxp3+) accumulation in dLNs with and without rOpn
administration. Values are expressed as mean ± SEM (n=5 mice per group),




























































ba In vitro pDCs
Supplemental Figure 3. Opn SLAYGR motif enhances pDC recruitment
in dLNs and IFN-β production in pDCs. (A) Gating strategy and
percentages of 7AAD–CD3-CD19-CD11c+PDCA-1+Siglec-H+ pDCs in dLNs
of tolerized mice treated with OVA or OVA/frOpn1 or OVA/frOpn3
(scrambled peptide: see Fig. 8A) for control. Mice were tolerized as in Fig.
3A. (B) Relative Ifnb expression to Hprt in pDCs conditioned in vitro with
OVA and OVA/rOpn. Values are expressed as mean ± SEM (n=10), pooled
data from three independent experiments.







Supplemental Table 1: Primers used for real-time PCR.
Supplemental Table 1
